Merck & Co., Inc.

MRKNYSE • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
130.36 USD
↘ 1.46 (1.11%)AT CLOSE (11:59 AM EDT)
129.97
↘ 0.39 (0.30%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
129.97
↘ 0.39 (0.30%)
🔴Market: CLOSED

Merck & Co., Inc. (MRK) trades at $130.63 per share. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics place MRK at a fair price relative to peers.

Technical & fundamental data as of Jul 29, 2026.

Open?$132.37
High?$132.69
Low?$129.65
Prev. Close?$131.82
Volume?7.5M
Avg. Volume?10.6M
VWAP?$130.90
Rel. Volume?0.71x
Bid / Ask
Bid?$129.30 × 100
Ask?$131.69 × 100
Spread?$2.39
Midpoint?$130.50
Valuation & Ratios
Market Cap?325.6B
Shares Out?2.5B
Float?2.4B
Float %?98.1%
P/E Ratio?36.44
P/B Ratio?7.10
EPS?$3.62
Dividend?2.53%
Ex-Dividend?N/A
News
Profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Infectious Disease & Vaccines
Employees
75.0K
Market Cap
325.6B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.merck.com
Listed
1949-04-20
Address
126 EAST LINCOLN AVENUE
RAHWAY, NJ 07065
Phone: 908-740-4000
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
91
Momentum?
8
Short Sent.?
63
Piotroski F-Score?1/9Weak
Altman Z-Score?3.98Safe
Confidence?58%Low
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?1.21%Low
Short Interest?29.4M
Days to Cover?3.4
Free Float2.4B
Avg Daily Volume8.6M
Settlement Date2026-07-15
Financial Health
Current Ratio?1.30Adequate
Quick Ratio?1.06Adequate
Cash Ratio?0.20Low
Debt/Equity?1.07Moderate
ValuationFAIRLY VALUEDvs 10 peers + S&P 500
Score
61/100
P/E?
Peers
40
S&P
20
36.4PRICEY▾
P/B?
Peers
50
S&P
26
7.10FAIR▾
P/S?
Peers
82
S&P
29
4.95FAIR▾
P/FCF?
Peers
56
S&P
45
23.1FAIR▾
EV/EBITDA?
Peers
50
S&P
29
19.2FAIR▾
EV/Sales?
Peers
82
S&P
31
5.62FAIR▾
Returns & Efficiency
ROE?
Peers
33
S&P
65
19.5%STRONG▾
ROA?
Peers
40
S&P
60
6.9%FAIR▾
Cash Flow & Enterprise
FCF?$14.1B
Enterprise Value?$369.4B
Fundamentals ratios updated end of day
MarketsMoversWatchlist